UNSPSC 51111741: Demecolcine

This classification denotes a colchicine-site binding agent with the molecular formula C21H25NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z01IVE25KI, chemically known as 6,7-dihydro-1,2,3,10-tetramethoxy-7-(methylamino)-benzo(alpha)heptalen-9(5h)-one but generally known as demecolcine, which bears US NIH Compound Identifier 2832. European Medicines Agency schedules Demecolcine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06964MIG.

UNSPSC 51111741 Demecolcine is a Commodity code, but the recent state and local opportunities posted under it do not reflect demecolcine procurement—instead, they capture a broader pharmaceutical and medical supply market where state and local governments are sourcing naloxone, first aid supplies, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. State and local issuing bodies soliciting under this code span county health departments (Seminole County, Florida), municipal fire rescue services (City of Tampa), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities). The work involves purchasing finished pharmaceutical products and medical consumables at volume for emergency response, community health, and institutional pharmacy benefit programs, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, and specific insurance coverage thresholds.

Recent activity includes Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 (due March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount cap), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon (due March 26, 2026, with awards effective July 1, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026). Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing reaching into Oregon. The code shows material recent activity but reflects pharmaceutical and medical supply procurement broadly rather than demecolcine specifically.